Free Trial

Moleculin Biotech Q3 2023 Earnings Report

Moleculin Biotech logo
$1.67 -0.14 (-7.73%)
(As of 12/20/2024 05:16 PM ET)

Moleculin Biotech EPS Results

Actual EPS
-$2.85
Consensus EPS
-$3.15
Beat/Miss
Beat by +$0.30
One Year Ago EPS
N/A

Moleculin Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Moleculin Biotech Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Moleculin Biotech Earnings Headlines

Moleculin Biotech Releases Corporate Presentation Update
Your bank is lying to you.
You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.
Moleculin Biotech Inc MBRX
See More Moleculin Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email.

About Moleculin Biotech

Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

View Moleculin Biotech Profile

More Earnings Resources from MarketBeat

Upcoming Earnings